AiM Medical Robotics has announced the unveiling of a magnetic resonance imaging (MRI)-compatible prototype of its “industry-first” robotics platform, a company press release states, as well as the receipt of funding from the Sontag Foundation’s Sontag Innovation Fund.
“The prototype is a testament to the progress that our company has made so far, bringing us closer to our goal of improving outcomes for patients undergoing neurosurgery and providing cost savings to hospitals by eliminating errors and reducing procedure times,” said Bob Cathcart, CEO of AiM. “The Sontag Foundation’s commitment to fund innovative advancements towards the treatment of brain tumours perfectly aligns with AiM’s core values, and we look forward to a fruitful collaboration.”
The Sontag Innovation Fund invests in early-stage and innovative technologies with the potential to drive cures, and improve the quality of life or life expectancy, for brain cancer patients.
This investment follows the close of AiM’s previous seed financing round, which was announced in March 2022.
“Dr [Julie] Pilitsis, Prof [Gregory] Fischer, and the AiM team, are developing a groundbreaking and innovative MRI-compatible robotics platform that has the potential to impact the lives of patients across neurological disorders,” said Scott Davis, senior associate of the Sontag Innovation Fund. “We are encouraged by the team and this technology, and hope the investment will attract additional external capital to improve the health status of brain cancer patients.”